Marcial: Is Eli Lilly Ripe for a Rebound?
This article is for subscribers only.
What's not to like about global pharmaceutical giant Eli Lilly (LLY)?
Bears on the stock would point to a number of things. Lilly could lose an estimated 36% of its 2008 revenues of $20.3 billion from patents expiring on Zyprexa and Cymbalta by 2013. And, as some bears assert, the success of Lilly's new Effient anti-clotting drug is questionable, as it has been linked to bleeding risks.